v3.26.1
Note 18 - Segment Information - Schedule of Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 30, 2026
Mar. 31, 2025
Dec. 31, 2025
Cash and cash equivalents $ 7,215   $ 669 $ 12,645
Prepaid expenses and other current assets 687     346
Property and equipment, net 12,644     12,641
Deferred offering costs 555     136
Licensed technology, net 2,243     2,243
Operating lease right-of-use assets, net 10,086     0
Goodwill 3,457     3,457
Other assets 210     124
Total consolidated assets of continuing operations 38,215     31,607
Research and development 1,854 $ 1,854 335  
Selling, general and administrative 3,780 3,780 1,042  
Total operating expenses 5,634 5,634 1,377  
Change in fair value of derivative liability 33 33 0  
Interest income 24 24 4  
Interest expense (648) (648) 0  
Net other (expense) income (591) (591) 4  
Net loss from operations before discontinued operations (6,225) (6,225) (1,373)  
Biopharma [Member]        
Cash and cash equivalents       12,277
Prepaid expenses and other current assets       156
Property and equipment, net       34
Deferred offering costs       136
Licensed technology, net       2,243
Operating lease right-of-use assets, net       0
Goodwill       0
Restricted cash       0
Other assets       124
Total consolidated assets of continuing operations       14,970
Research and development   857 335  
Selling, general and administrative   2,054 1,042  
Total operating expenses   2,911 1,377  
Change in fair value of derivative liability   33 0  
Interest income   24 4  
Interest expense   (648) 0  
Net other (expense) income   (591) 4  
Net loss from operations before discontinued operations   (3,502) (1,373)  
CDMO [Member]        
Cash and cash equivalents       368
Prepaid expenses and other current assets       190
Property and equipment, net       12,607
Deferred offering costs       0
Licensed technology, net       0
Operating lease right-of-use assets, net       0
Goodwill       3,457
Restricted cash       0
Other assets       0
Total consolidated assets of continuing operations       16,622
Research and development   997 0  
Selling, general and administrative   1,726 0  
Total operating expenses   2,723 0  
Change in fair value of derivative liability   0 0  
Interest income   0 0  
Interest expense   0 0  
Net other (expense) income   0 0  
Net loss from operations before discontinued operations   $ (2,723) $ 0  
Continuing Operations [Member]        
Cash and cash equivalents 7,215     12,645
Prepaid expenses and other current assets 687     346
Property and equipment, net 12,644     12,641
Deferred offering costs 555     136
Licensed technology, net 2,993     2,243
Operating lease right-of-use assets, net 10,086     0
Goodwill 3,457     3,457
Restricted cash 368     0
Other assets 210     124
Total consolidated assets of continuing operations 38,215     $ 31,592
Continuing Operations [Member] | Biopharma [Member]        
Cash and cash equivalents 6,937      
Prepaid expenses and other current assets 233      
Property and equipment, net 30      
Deferred offering costs 555      
Licensed technology, net 2,993      
Operating lease right-of-use assets, net 0      
Goodwill 0      
Restricted cash 368      
Other assets 126      
Total consolidated assets of continuing operations 11,242      
Continuing Operations [Member] | CDMO [Member]        
Cash and cash equivalents 278      
Prepaid expenses and other current assets 454      
Property and equipment, net 12,614      
Deferred offering costs 0      
Licensed technology, net 0      
Operating lease right-of-use assets, net 10,086      
Goodwill 3,457      
Restricted cash 0      
Other assets 84      
Total consolidated assets of continuing operations $ 26,973